Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer

Cancer Research

Volumn 67, Issue 10, 2007, Pages 4843-4850

  Van Vlerken, Lilian E ^a   Duan, Zhenfeng ^b   Seiden, Michael V ^b   Amiji, Mansoor M ^a,c  

^a NORTHEASTERN UNIVERSITY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c 110 Mugar Life Sciences Building ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CERAMIDE; ETHYLENE OXIDE DERIVATIVE; NANOPARTICLE; PACLITAXEL; POLYCAPROLACTONE;

APOPTOSIS; ARTICLE; CHEMOSENSITIZATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG METABOLISM; ENCAPSULATION; HUMAN; HUMAN CELL; IC 50; OVARY CANCER; POLYMERIZATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CERAMIDES; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ETHYLENE OXIDE; FEMALE; HUMANS; LACTONES; NANOPARTICLES; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 34250303805     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1648     Document Type: Article

References (39)

1. Bradley G, Juranka PF, Ling V. Mechanism of multidrug resitance. Biochem Biophys Acta 1988;948: 87-128.
2. Goldstein LJ, Galski H, Fojo A, et al. Expession of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989;81:116-24.
3. Harris AL, Hochhauser D. Mechanisms of multidrug resistance in cancer treatment. Acta Oncol 1992;31:205-13.
4. Chawla JS, Amiji MM. Biodegradable poly(epsilon-caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen. Int J Pharm 2002;249:127-38.
5. Chawla JS, Amiji MM. Cellular uptake and concentrations of Tamoxifen upon administration in poly(epsilon-caprolactone) nanoparticles. AAPS Pharmsci 2003;5: article 1.
6. Woodward SC, Brewer PS, Moatamed R, Schindler A, Pitt CG. The intracellular degradation of poly(epsilon-caprolactone) nanoparticles. J Biomed Mater Res 1985; 19:437-44.
7. Pitt CG, Gratzi M, Kimmel GL, Surles J, Schindler A. Aliphatic polyesters II. The degradation of poly (DL-lactide), poly(epsilon-caprolactone), and their copolymers in vivo. Biomaterials 1981;2:215-20.
8. Serrano MC, Pagani R, Vallet-Regi M, et al. In vitro biocompatibility assessment of poly(epsilon-caprolactone) films using L929 mouse fibroblasts. Biomaterials 2004;25:5603-11.
9. Uhrich KE, Cannizzaro SM, Langer RS, Shakesheff KM. Polymeric systems for controlled drug release. Chem Rev 1999;99:3181-98.
10. Shenoy DB, Amiji MM. Poly(ethylene oxide)-modified poly(epsilon caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. Int J Pharm 2005; 293:261-70.
11. Ferrari M. Cancer nanotechnology: opportunities and challanges. Nat Rev Cancer 2005;5:161-71.
12. Shenoy D, Little S, Langer R, Amiji M. Poly(ethylene oxide)-modified poly(β amino ester) nanoparticles as a pH sensitive system for tumor-targeted delivery of hydrophobic drugs: part 2. In vivo distribution and tumor localization studies. Pharm Res 2005;22:2107-14.
13. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents: VI. The isolation and structure of taxol, a novel antitumor and anitleukemic agent from Taxus brevifolia. J Am Chem Soc 1971;18:242-60.
14. Khayat D, Antoine EC, Coeffic D. Taxol in the management of cancers of the breast and the ovary. Cancer Invest 2000;18:242-60.
15. Bhalla KN. Microtubule-targeted anticancer agents and apoptosis. Oncogene 2003;22:9075-86.
16. 2-M arrest and apoptosis. Exp Cell Res 1998;241:96-101.
17. Charles AG, Han TY, Liu YY, Hansen N, Giuliano AE, Cabot MC. Taxol-induced ceramide generation and apoptosis in human breast cancer cells. Cancer Chemother Pharmacol 2001;47:444-50.
18. Senchenkov A, Litvak DA, Cabot MC. Targeting ceramide metabolism - a strategy for overcoming drug resistance. J Nat Cancer Inst 2001;93:347-57.
19. Kolesnick R, The therapeutic potential of modulating the ceramide/sphingomyelin pathway. J Clin Invest 2002;110:3-8.
20. Sietsma H, Veldman RJ, Kok JW. The involvement of sphingolipids in multidrug resistance. J Membr Biol 2001;181:153-162.
21. Selzner M, Bielawska A, Morse MA, et al. Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Res 2001;61:1233-40.
22. Tilly JL, Kolesnick RN. Sphingolipids, apoptosis, cancer treatments and the ovary: investigating a crime against female fertility. Biochem Biophys Acta 2002; 1585:135-58.
23. Reynolds CP, Maurer BJ, Kolesnick RN. Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett 2004;206:169-80.
24. Radin NS. Killing tumors by ceramide-induced apoptosis: a crituque of available drugs. Biochem J 2003;371:243-56.
25. von Haefen C, Wieder T, Gillissen B, et al. Ceramide induces mitochondrial activation and apoptosis via a Bax-dependant pathway in human carcinoma cells. Oncogene 2002;21:4009-19.
26. Liu Y-Y, Han T-Y, Giuliano AE, Cabot MC. Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J 2001;15:719-30.
27. Morjani H, Aouali N, Belhoussine R, Veldman RJ, Levade T, Manfait M. Elevation of glucosylceramide in multidrug-resistant cancer cells and accumulation in cytoplasmic droplets. Int J Cancer 2001;94:157-65.
28. Lavie Y, Cao H, Volner A, et al. Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting cermide glycosylation in human cancer cells. J Biol Chem 1997;272:1682-7.
29. Lucci A, Cho WI, Han TY, Giuliano AE, Morton DL, Cabot MC. Glucosylceramide: a marker for multiple-drug resistant cancers. Anticancer Res 1998; 18:475-80.
30. Itoh M, Kitano T, Watanabe M, et al. Possible role of cermide as an indicator of chemoresistance: decrease of the ceramide content via activation of glucosylceramide synthase and sphingomyelin synthase in chemoresistant leukemia. Clin Cancer Res 2003;9:415-23.
31. Hua W, Christianson T, Rougeot C, Rochefort H, Clinton GM. SKOV3 ovarian carcinoma cells have functional estrogen receptor but are growth-resistant to estrogen and antiestrogens. J Steroid Biochem Mol Biol 1995;55:279-89.
32. Shenoy D, Little S, Langer R, Amiji M. Poly(ethylene oxide)-modified poly(β amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: Part I. In vitro evaluations. Mol Pharm 2005;2:357-66.
33. Wang Y, Hao D, Stein WD, Yang L. A kinetic study of Rhodamine-123 pumping by P-glycoprotein. Biochem Biophys Acta 2006;1758:1671-6.
34. Thon L, Mohlig H, Mathieu S, et al. Ceramide mediates caspase-independent programmed cell death. FASEB J 2005;19:1945-56.
35. Granot T, Milhas D, Carpentier S, et al. Caspase-dependent and -independent cell death of Jurkat human leukemia cells induced by novel synthetic cermide analogs. Leukemia 2006;20:392-9.
36. Kim WH, Choi CH, Kang SK, Kwon CH, Kim YK. Ceramide induces non-apoptotic cell death in human glioma cells. Neurochem Res 2005;30:969-79.
37. Ganasia-Leymarie V, Bischoff P, Bergerat JP, Holl V. Signal transduction pathways of taxanes-induced apoptosis. Curr Med Chem Anti-Cane Agents 2003;3: 291-306.
38. Siskind LJ. Mitochondrial ceramide and the induction of apoptosis. J Bioeng Biomembr 2005;37:143-53.
39. Jacotot E, Costantini P, Laboureau E, Zamzami N, Susin SA, Kroemer G. Mitochondrial membrane permeabilization during the apoptotic process. Ann N Y Acad Sci 1999;887:18-30.